Stories
Prime leaders appear on PCMA’s podcast on topic “Understanding the value of biosimilars”
Prime’s Dr. Joseph Leach and Jarrod Henshaw discuss the opportunity, how the company’s new MedDrive™ medical drug management product will help manage growing specialty spend
September 8, 2021Today, spending on biologic drugs makes up 43% of total drug spending. This is a growing area of new innovation for a multitude of therapeutic areas, and also an area of growing cost. To increase the use of biosimilars, strategies must be implemented to focus on biologics and drive cost-savings. To share these strategies, Prime’s Dr. Joseph Leach, senior vice president and chief medical officer and Jarrod Henshaw, senior vice president and Innovation & Supply Chain Officer joined JC Scott, executive director of Pharmaceutical Care Management Association (PCMA) and host of The Pharmacy Benefit podcast. Prime Therapeutics recently announced a major program addressing the increased use of biosimilars. Henshaw explains the differences between traditional drugs vs. biologics and generics drugs vs. biosimilars. Both discuss what it means for biosimilars to be interchangeable, how they confront fears and misperceptions on biosimilars, what roles PBMs must play to drive the cost-savings from adoption of biosimilars, and how policies and incentives can encourage the use of biosimilars.
Related news
Stories
September 15, 2023
Prime, Magellan Rx Offer Value Plus to Help States Negotiate Value-Based Contracts for CGTs
Reprinted with permission from MMIT By Angela Maas As more and more high-cost…
Stories
September 15, 2023
Prime Therapeutics ranked No. 3 on Minnesota top private companies list
The Minneapolis/St. Paul Business Journal named Prime Therapeutics (Prime) to its annual list,…
Stories
September 5, 2023
Prime Together Foundation: Helping students achieve their dreams
Since 2002, Achieve Twin Cities has equipped more than 85,000 high school students…